Nichi-Iko Pharmaceutical

Nichi-Iko Pharmaceutical is a Japanese pharmaceutical company focused primarily on the development, manufacturing, and commercialization of generic medicines. The company is one of Japan's major generic-drug manufacturers and operates across product development, production, quality assurance, distribution, and medical information services. Its business is centered on marketed products rather than a traditional innovative clinical pipeline, with a broad portfolio of oral and external-use generic pharmaceuticals. Nichi-Iko has also built manufacturing and supply capabilities through domestic subsidiaries and past international expansion, although it announced the transfer of Sagent Pharmaceuticals and Omega Laboratories in 2023. The company emphasizes manufacturing quality, stable supply, and cost-effective products for the healthcare system.